Atelocollagen-mediated systemic DDS for nucleic acid medicines.

Ann N Y Acad Sci

Formulation Laboratories, Technology Research and Development Center, Dainippon Sumitomo Pharma Co., Ltd., Ibaraki, Osaka 567-0878, Japan.

Published: October 2006

The goal of our research is to provide a practical platform for drug delivery in oligonucleotide therapy. We report here the efficacy of an atelocollagen-mediated oligonucleotide delivery system applied to systemic siRNA and antisense oligonucleotide treatments in animal disease models. Atelocollagen and oligonucleotides formed a complex of nanosized particles, which was highly stable against nucleases. The complex allowed oligonucleotides to be delivered efficiently into several organs and tissues via intravenous administration. In a tumor metastasis model, the complex successfully delivered siRNA to metastasized tumors in bone tissue and inhibited their growth. We also demonstrated that a single intravenous treatment of the antisense oligodeoxynucleotide complex suppressed ear dermatitis in a contact hypersensitivity model. These results indicate the strong potential of the atelocollagen-mediated drug delivery system for practical therapeutic technology.

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1348.010DOI Listing

Publication Analysis

Top Keywords

drug delivery
8
delivery system
8
atelocollagen-mediated systemic
4
systemic dds
4
dds nucleic
4
nucleic acid
4
acid medicines
4
medicines goal
4
goal provide
4
provide practical
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!